The FDA has approved Xcovery Holdings' ALK inhibitor Ensacove for first-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell ...
READ MORENew drugs in the US were, on average, approved months before winning approval in the EU, according to new data from The IQVIA Institute for Human Data Science.
READ MOREIonis’ antisense oligonucleotide olezarsen is now the first approved treatment for familial chylomicronemia syndrome, a rare metabolic disorder that prevents the body from breaking down ...
READ MOREWelcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
READ MORE
